Yasnot Acosta, María FernandaAlvear Cardona, Joy Smith2021-07-152021-07-152021-07-10https://repositorio.unicordoba.edu.co/handle/ucordoba/4324The Pfizer-BioNTech vaccine works with an mRNA mechanism in a lipid envelope, so that when administered it is recognized by the immune system and anti-SARSCoV2 "S" protein antibodies are produced. This study was performed to quantify the production of anti-protein "S" antibodies before and after vaccination, to compare the process of response to the vaccine and its effectiveness Materials. Human serum samples from 18 volunteers, both men and women, all health workers from the city of Monteria, were used; they were taken in duplicate, it means, 36 samples and were collected between the months of March and June Method. The 36 serum samples collected were deposited in 300µ vials for subsequent quantification of IgG and IgM anti-protein "S" antibodies, this was done with a difference of 60 days between each sample and the chemiluminescence technique was used to quantify/measure the antibodies Results. It was found that in the samples of the 18 volunteers the IgG type antibodies were increased at day 60 in values ranging from 100 to 50,000 times with respect to the samples of day zero, or the initial sample Conclusion. The production of antiprotein "S" antibodies generated as immune response by the vaccine was successful, thus declaring that the vaccine proved to be an effective method with respect to its function or immunization objective.1. INTRODUCCIÓN…………………………………………………………………………72. OBJETIVOS……………………………………………………………………………….92 .1 objetivo general2.2 objetivos específicos3. MATERIALES Y MÉTODOS……………………………………………………………103.1 tipo de estudio………………………………………………………………...…….103.2 Aspectos éticos……………………………………………………………………...114. RESULTADOS……………………………………………………………………………124.1 interpretación de resultados……………………………………………………..…135. DISCUSIÓN………………………………………………………………………………176. CONCLUSIÓN……………………………………………………………………………197. RECOMENDACIONES………………………………………………………………….208. AGRADECIMIENTOS……………………………………………………………………219. BIBLIOGRAFÍA…………………………………………………………………………...22application/pdfspaCopyright Universidad de Córdoba, 2021Artículo de revistainfo:eu-repo/semantics/openAccessAtribución-NoComercial-SinDerivadas 4.0 Internacional (CC BY-NC-ND 4.0)InmunizaciónVacuna PfizerAnticuerposProteínaEficienciaimmunizationPfizer vaccineAntibodiesProteinEfficiency